CureVac N.V. (CVAC)

NASDAQ: CVAC · IEX Real-Time Price · USD
3.470
+0.040 (1.17%)
At close: Feb 20, 2024, 4:00 PM
3.400
-0.070 (-2.02%)
After-hours: Feb 20, 2024, 6:36 PM EST
1.17%
Market Cap 776.87M
Revenue (ttm) 45.62M
Net Income (ttm) -321.59M
Shares Out 223.88M
EPS (ttm) -1.59
PE Ratio n/a
Forward PE 9.17
Dividend n/a
Ex-Dividend Date n/a
Volume 393,374
Open 3.400
Previous Close 3.430
Day's Range 3.390 - 3.510
52-Week Range 3.350 - 12.360
Beta 2.58
Analysts Hold
Price Target 15.00 (+332.28%)
Earnings Date Nov 14, 2023

About CVAC

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncyti... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 14, 2020
Employees 904
Stock Exchange NASDAQ
Ticker Symbol CVAC
Full Company Profile

Financial Performance

In 2022, CureVac's revenue was 67.42 million, a decrease of -34.54% compared to the previous year's 102.99 million. Losses were -249.03 million, -39.51% less than in 2021.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CVAC stock is "Hold." The 12-month stock price forecast is $15.0, which is an increase of 332.28% from the latest price.

Price Target
$15.0
(332.28% upside)
Analyst Consensus: Hold
Stock Forecasts

News

CureVac stock gains as COVID vaccine candidates show promise

CureVac N.V. shares CVAC, +1.20% gained 3% premarket on Friday as the company released new data from a trial of its mRNA COVID-19 vaccine candidates, which it is developing in collaboration with GSK P...

6 weeks ago - Market Watch

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile Monovalent mRNA vaccine candidate, ...

6 weeks ago - Accesswire

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE Decision does not affect ongoing litigation in Germany regarding seven other ...

2 months ago - Accesswire

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine can...

3 months ago - Accesswire

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

COVID-19 Phase 2 clinical trial fully enrolled Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine First participant dosed in seasonal flu Phase 2 part of...

3 months ago - Accesswire

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech Ruling on infringement to be provided latest once the validity...

5 months ago - Accesswire

CureVac signals progress on mRNA flu vaccine

CureVac NV CVAC, -3.85% said Tuesday that it has selected an mRNA flu vaccine candidate for continued clinical development, based on positive results from an early-stage study conducted in collaborati...

5 months ago - Market Watch

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate Best-performing candidate providing broad...

5 months ago - Accesswire

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Initiated Ph...

6 months ago - Accesswire

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates Vaccine candidates developed in collaboration with GSK within COVID-19 vaccine deve...

7 months ago - Accesswire

Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology

NEW YORK--(BUSINESS WIRE)--Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically de...

7 months ago - Business Wire

CureVac Announces Update to the Management Team

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on m...

7 months ago - Accesswire

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in German...

7 months ago - Accesswire

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma Study designed to evaluate safety and immunogenici...

8 months ago - Accesswire

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 20, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on m...

8 months ago - Accesswire

CureVac Announces Voting Results of General Meeting

TÜBINGEN, GERMANY and BOSTON, USA / ACCESSWIRE / June 19, 2023 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based ...

8 months ago - Accesswire

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Filed infringement...

9 months ago - Accesswire

CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology

CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc and BioNTech over the use of mRNA technology and that a U.S. court had granted its request to transfer t...

9 months ago - Reuters

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline CureVac is filing counterclaim in U.S....

9 months ago - Accesswire

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antig...

10 months ago - Accesswire

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

In 2022, ongoing business transformation driven by COVID-19 and flu clinical develop­ments in collaboration with GSK and successful broadening of oncology footprint Early 2023, strong validation of Cu...

10 months ago - Accesswire

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2023 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucle...

11 months ago - Accesswire

CureVac Announces Voting Results of Extraordinary General Meeting

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 28, 2023 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based ...

11 months ago - Accesswire

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 10, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based ...

1 year ago - Accesswire

CureVac Announces Proposed Public Offering of Common Shares

TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / February 7, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...

1 year ago - Accesswire